Xilio Therapeutics to Present at Stifel 2026 Healthcare Conference

WALTHAM, Mass., Nov. 03, 2026 /CourierPR/ -- Xilio Therapeutics, a clinical-stage biotechnology company focused on developing masked immuno-oncology therapies, will present at the Stifel 2026 Healthcare Conference. The presentation is scheduled for Tuesday, November 10, 2026, at 2:40 p.m. Eastern Time.

Xilio Therapeutics aims to improve outcomes for cancer patients through its innovative masking technology, which is designed to activate selectively within the tumor microenvironment, reducing systemic side effects. The company’s management will provide insights into its ongoing research and development efforts during the conference.

Attendees will have the opportunity to access a live webcast of the presentation through the "Events & Presentations" section on the Xilio Therapeutics website at ir.xiliotx.com. A replay will be available for 30 days following the event.

Xilio Therapeutics was founded with the goal of discovering and developing therapies that offer significant benefits to cancer patients without the harsh side effects of current immunotherapy treatments. The company’s approach is based on its clinically-validated masking technology, which it believes can achieve durable efficacy in a targeted manner.

The presentation at the Stifel 2026 Healthcare Conference is part of Xilio Therapeutics’ ongoing efforts to engage with the broader healthcare community and share its progress. The company’s management will discuss the latest developments in its pipeline and the potential impact of its therapies on the treatment of cancer.

By participating in this conference, Xilio Therapeutics aims to further its mission of improving the lives of cancer patients through innovative and targeted therapies.